1312312-76-7

Basic information

• Product Name: 2-chloro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside
• Synonyms: 2-chloro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside
• CAS NO: 1312312-76-7
• Molecular Weight: 574.972
• Mol File: 1312312-76-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-chloro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside(1312312-76-7)
• EPA Substance Registry System: 2-chloro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside(1312312-76-7)

Safety Data

• Hazardous Substances Data: 1312312-76-7(Hazardous Substances Data)

Upstream product

• 754214-56-7 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1312312-40-5 2-chloro-4-iodophenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside 
• 121238-27-5 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl trichloroimidate 
• 116130-33-7 2-chloro-4-iodophenol 

Downstream Products

• 1312312-77-8 2-chloro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl α-D-mannopyranoside 

Relevant articles and documents

Antiadhesion therapy for urinary tract infections-A balanced PK/PD profile proved to be key for success

The initial step for the successful establishment of urinary tract infections (UTIs), predominantly caused by uropathogenic Escherichia coli, is the adhesion of bacteria to urothelial cells. This attachment is mediated by FimH, a mannose-binding adhesin, which is expressed on the bacterial surface. To date, UTIs are mainly treated with antibiotics, leading to the ubiquitous problem of increasing resistance against most of the currently available antimicrobials. Therefore, new treatment strategies are urgently needed, avoiding selection pressure and thereby implying a reduced risk of resistance. Here, we present a new class of highly active antimicrobials, targeting the virulence factor FimH. When the most potent representative, an indolinylphenyl mannoside, was administered in a mouse model at the low dosage of 1 mg/kg (corresponding to approximately 25 μg/mouse), the minimal therapeutic concentration to prevent UTI was maintained for more than 8 h. In a treatment study, the colony-forming units in the bladder could be reduced by almost 4 orders of magnitude, comparable to the standard antibiotic treatment with ciprofloxacin (8 mg/kg, sc).